Personalis’s liquid biopsy is part of a growing market for minimal residual disease assays, tests that look for any remaining cancer cells after the initial treatment. Tempus AI has been the commercial partner on this Personalis test since 2023.
Israeli cancer diagnostics startup SpotitEarly launched in the U.S. It is developing a test that uses AI and trained canines to analyze patients’ breath samples, with the goal of detecting cancer at its earliest stages. The company plans to begin selling the at-home test to U.S. consumers next year.
We'll explore why the next era of payer performance will depend on building a trusted data foundation that connects people, providers, and relationships across the enterprise.